Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK’s MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
MUSCA study shows asthma patients achieved improvements in their health-related quality of life and lung function with Nucala® (mepolizumab).
Read more -
GSK confirms closure of agreement to divest anaesthesia portfolio to Aspen
GSK today announced the closure of an agreement with Aspen aligned with GSK’s strategy of simplification through focusing on core therapeutic areas.
Read more -
Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma
Positive headline results from a non-inferiority lung function study
Read more -
ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment
Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference
Read more -
Results announcement for the fourth quarter 2016
View full Q4 2016 Results (PDF)
Read more -
Abbas Hussain to leave GSK
Abbas Hussain, President, Global Pharmaceuticals has decided to leave the company.
Read more -
Luke Miels appointed President, Global Pharmaceuticals, GSK
Luke Miels has been appointed President, Global Pharmaceuticals, GSK.
Read more -
GSK confirms closure of agreement to divest non-core assets to Aspen
GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN) and certain of its subsidiaries (“Aspen”), which...
Read more -
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention
First injectable to be studied for efficacy in pre-exposure prophylaxis
Read more -
GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma
The start of a phase III study investigating the effects of once-daily closed triple combination therapy (FF/UMEC/VI).
Read more -
GSK announces Board changes
the creation of a new Board committee and a number of changes to the membership of the Board and its committees
Read more -
ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen
First phase III studies to show efficacy of two-drug regimen as maintenance therapy
Read more -
ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe
The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.
Read more -
GSK submits regulatory application in Japan for belimumab in systemic lupus erythematosus
Belimumab is a human monoclonal antibody that selectively targets B-lymphocyte stimulator an important factor in the survival of B cells.
Read more -
GSK opens new global vaccines R&D center in Rockville, MD, USA
New state-of-the-art facility will house 450 scientists and support staff, creating up to 200 new jobs.
Read more -
Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him
After seven years as CEO of ViiV Healthcare, Dr Dominique Limet will step down at the end of March 2017.
Read more -
Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
Relvar is a combination of the inhaled corticosteroid, fluticasone furoate, and the long-acting beta2 agonist, vilanterol ‘VI’.
Read more -
GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
The filing by GSK of a regulatory submission closed triple combination therapy FF/UMEC/VI 100/62.5/25 mcg for patients with COPD.
Read more -
GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Tthe regulatory submission of a MMA to the EMA seeking approval for ShingrixTM.
Read more -
GSK starts phase III programme with daprodustat for anaemia associated with chronic kidney disease
The start of a phase III development programme investigating daprodustat as a treatment for anaemia associated with CKD.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
